AnGes, Inc. Logo

AnGes, Inc.

Biopharmaceutical firm developing gene-based and nucleotide-based medicines.

4563 | T

Overview

Corporate Details

ISIN(s):
JP3127700007
LEI:
Country:
Japan
Address:
茨木市彩都あさぎ七丁目7番15号

Description

AnGes, Inc. is a biopharmaceutical company specializing in the research and development of gene-based and nucleotide-based medicines. The company's core focus is its Hepatocyte Growth Factor (HGF) gene therapy product, designed to treat ischemic diseases by regenerating blood vessels. This product was the first gene therapy medicine to receive marketing approval in Japan. AnGes leverages its expertise in plasmid DNA technology across its development pipeline, which also includes an NFkB decoy oligonucleotide and DNA vaccines. The company is dedicated to developing novel treatments for various conditions, including rare diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-11-07 07:30
有価証券届出書(参照方式)
Japanese ZIP 244.5 KB
2025-08-13 06:50
確認書
Japanese ZIP 8.9 KB
2025-08-13 04:19
半期報告書-第27期(2025/01/01-2025/12/31)
Japanese ZIP 488.0 KB
2025-03-31 04:52
臨時報告書
Japanese ZIP 25.5 KB
2025-03-31 03:22
内部統制報告書-第26期(2024/01/01-2024/12/31)
Japanese ZIP 23.7 KB
2025-03-31 03:18
確認書
Japanese ZIP 8.9 KB
2025-03-31 03:17
有価証券報告書-第26期(2024/01/01-2024/12/31)
Japanese ZIP 1.5 MB
2024-09-03 06:05
訂正有価証券届出書(参照方式)
Japanese ZIP 203.2 KB
2024-08-30 09:06
有価証券届出書(参照方式)
Japanese ZIP 381.2 KB
2024-08-14 02:28
確認書
Japanese ZIP 8.9 KB
2024-08-14 02:27
半期報告書-第26期(2024/01/01-2024/12/31)
Japanese ZIP 725.7 KB
2024-05-14 02:27
確認書
Japanese ZIP 8.9 KB
2024-05-14 02:25
四半期報告書-第26期第1四半期(2024/01/01-2024/03/31)
Japanese ZIP 457.7 KB
2024-03-29 01:45
臨時報告書
Japanese ZIP 24.0 KB
2024-03-29 01:43
内部統制報告書-第25期(2023/01/01-2023/12/31)
Japanese ZIP 23.6 KB

Automate Your Workflow. Get a real-time feed of all AnGes, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AnGes, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AnGes, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ABEONA THERAPEUTICS INC. Logo
A clinical-stage biopharma developing cell and gene therapies for rare diseases.
United States of America
ABEO
ABINGDON HEALTH PLC Logo
A CDMO specializing in lateral flow assays, offering development to manufacturing services.
United Kingdom
ABDX
ABIONYX Pharma Logo
Develops biotherapies and drug delivery vectors using apolipoprotein A-I.
France
ABNX
ABIVAX Logo
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
France
ABVX
Abivax S.A. Logo
Clinical-stage biotech developing miRNA therapeutics for inflammatory diseases.
United States of America
ABVX
ABL Diagnostics Logo
Develops molecular diagnostic solutions for managing infectious diseases.
France
ABLD
Abliva Logo
Biopharmaceutical company developing medicines for primary mitochondrial diseases.
Sweden
ABLI
AB Science Logo
Researches and develops protein kinase inhibitors for human and veterinary medicine.
France
AB
ABVC BIOPHARMA, INC. Logo
Develops botanical drugs and medical devices for oncology, ophthalmology, and CNS.
United States of America
ABVC
ACADIA PHARMACEUTICALS INC Logo
Biopharmaceutical company developing medicines for CNS disorders and rare diseases.
United States of America
ACAD

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.